Investor Presentaiton
Our industry leading position in protein degradation is
driven by portfolio breadth and depth of expertise
Industry-leading capabilities
Molecular
glue
Target
protein
Molecular
glue
molecule
E3
ligase
CELMOD
evotec
Berkeley
UNIVERSITY OF CALIFORNIA
Hetero-
bifunctional
Target
protein
ADC
degrader
Cysteine residue
E3 ligase
• Drug-Linker
LDD
SGC
A-ALPHA BIO
Full
Development
Early
Development
CELMOD ADC
IND-enabling
studies
SyntheX
Targeting the undruggable
AMPHISTA
THERAPEUTICS
Industry-leading pipeline
iberdomide:
Multiple Myeloma
golcadomide:
Lymphoma
CK1a:
Acute Myeloid Leukemia
BCL6 LDD:
Lymphoma
HbF CELMOD:
Sickle Cell Disease
CELMOD
Solid Tumors
Discuss today
mezigdomide:
Multiple Myeloma
AR LDD:
Prostate
Helios:
Solid Tumors
LDD:
Prostate
LDD:
Autoimmune
>15 pre-clinical programs across multiple therapeutic areas
Potential to efficiently deliver -4 INDS annually and expand beyond Heme/Onc targets (Immunology, CV, Neuroscience)
Ill Bristol Myers Squibb™
Not for Product Promotional Use
34View entire presentation